Immunovant Proof-of-Trial for IMCT-1402 Misses Primary Endpoint

By Chris WackImmunovant said it saw negative topline results from Period 1 of its proof-of-concept trial evaluating IMVT-1402 imeroprubart for the treatment of cutaneous lupus erythematosus.The company said the study didn't achieve statistical significance on its primary endpoint of percent change…